In a remarkable display of resilience and innovation, Jordan’s pharmaceutical industry has defied regional headwinds to record a stellar 14.8% growth in exports during 2024. Despite supply chain disruptions triggered by regional unrest, the sector surged to an impressive JD611 million, reinforcing its status as a beacon of stability and forward-thinking in the Middle East.
Tracing its roots back to 1962 in Salt, Jordan’s pharmaceutical industry is one of the oldest in the Arab world. Today, it stands as a testament to decades of innovation and determination, exporting a staggering 80% of its production across 85 global markets. Key destinations include powerhouses like Saudi Arabia, Iraq, the United States, and the UAE, underscoring the industry’s widespread appeal and rigorous adherence to international quality standards.
Fadi Atrash, representing the therapeutic industries and medical supplies sector at the Jordan Chamber of Industry, highlights that the sector has weathered regional instability and thrived by embracing innovation. In 2024, companies introduced new, cutting-edge drug categories, propelling the industry into the second-fastest growing industrial export sector in the Kingdom. Atrash talks about the important role that strategic initiatives under the Economic Modernization Vision (EMV) played in boosting confidence and demand both at home and abroad. These initiatives sped up the registration process and created new market opportunities.
The industry’s impressive infrastructure is evident in its 27 specialized facilities, which collectively boast an annual production capacity of JD1.5 billion. With a registered capital of JD280 million and a dynamic workforce of approximately 7,000 professionals—of whom 35% are women—Jordan’s pharmaceutical sector is not only a driver of economic growth but also a model of inclusivity and talent development.
Looking ahead, the EMV sets ambitious targets: by 2033, the sector aims to employ 16,000 individuals and boost exports by 20.3% annually, potentially reaching JD2.1 billion—an exponential leap from JD200 million in 2021. Additional goals include attracting JD1.1 billion in new investments and elevating the sector’s GDP contribution from JD536 million to JD1.7 billion. These initiatives are designed to enhance productivity, reduce operational expenses, and cultivate specialized talent, ensuring that the industry remains competitive on a global scale.
Jordan’s pharmaceutical renaissance is a story of turning challenges into opportunities—a narrative of steadfast commitment, technological advancement, and economic vision that continues to inspire the region and beyond.
